Literature DB >> 35249158

Pulmonary neuroendocrine tumors: study of 266 cases focusing on clinicopathological characteristics, immunophenotype, and prognosis.

Shuwen Zhang1, Jingjing Chen1,2, Rui Zhang1, Liqin Xu1, Yan Wang3, Zaixin Yuan1,2, Xiaohui Hou1,2, Jian Feng4.   

Abstract

OBJECTIVE: Pulmonary neuroendocrine tumors (PNETs) consist of small-cell lung cancer (SCLC), large-cell neuroendocrine carcinoma (LCNEC), typical carcinoid (TC), and atypical carcinoid (AC). We aimed to analyze the immunophenotypic, metastatic, and prognostic risk factors for PNETs.
MATERIALS AND METHODS: A total of 266 patients with PNETs were enrolled, including 219 patients with SCLC, 18 patients with LCNEC, 11 patients with TC, and 18 patients with AC. Clinicopathological characteristics and immunophenotypes were compared among the subtypes of PNETs. Risk factors for metastasis, progression-free survival (PFS), and overall survival (OS) were analyzed.
RESULTS: Thyroid transcription factor-1 (TTF-1) and the Ki-67 index were significantly different among subtypes of PNETs (all P < 0.05). Smoking (OR, 2.633; P = 0.031), high pretreatment carcinoembryonic antigen (CEA > 5 ng/ml: OR, 3.084; P = 0.014), and poorly differentiated pathotypes (P = 0.001) were independent risk factors for lymph-node metastasis. Smoking (OR, 2.071; P = 0.027) and high pretreatment CEA (OR, 2.260; P = 0.007) were independent risk factors for distant metastasis. Results of the multivariate Cox regression model showed pretreatment CEA (HR, 1.674; P = 0.008) and lymphocyte-monocyte ratio (LMR) (HR = 0.478, P = 0.007) were significantly associated with PFS; BMI (P = 0.031), lymph-node metastasis (HR = 4.534, P = 0.001), poorly differentiated pathotypes (P = 0.015), platelet-lymphocyte ratio (PLR) (HR = 2.305, P = 0.004), and LMR (HR = 0.524, P = 0.045) were significantly associated with OS.
CONCLUSIONS: PNETs are a group of highly heterogeneous tumors with different clinical manifestations, pathological features, and prognoses. Knowing clinicopathological characteristics and immunophenotypes of PNETs is significant for diagnosis. Pretreatment PLR, LMR, and CEA have certain value in the prognosis of PNETs.
© 2022. The Author(s).

Entities:  

Keywords:  Carcinoembryonic antigen; Clinicopathological characteristics; Lymphocyte–monocyte ratio; Overall survival; Platelet–lymphocyte ratio; Pulmonary neuroendocrine tumor

Year:  2022        PMID: 35249158     DOI: 10.1007/s00432-022-03970-x

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  41 in total

1.  Prognostic factors in a multicentre study of 247 atypical pulmonary carcinoids.

Authors:  Niccolò Daddi; Marco Schiavon; Pier Luigi Filosso; Giuseppe Cardillo; Marcello Carlo Ambrogi; Angela De Palma; Luca Luzzi; Alessandro Bandiera; Christian Casali; Alberto Ruffato; Verena De Angelis; Luigi Gaetano Andriolo; Francesco Guerrera; Francesco Carleo; Federico Davini; Moira Urbani; Sandro Mattioli; Uliano Morandi; Piero Zannini; Giuseppe Gotti; Michele Loizzi; Francesco Puma; Alfredo Mussi; Alberto Ricci; Alberto Oliaro; Federico Rea
Journal:  Eur J Cardiothorac Surg       Date:  2013-10-06       Impact factor: 4.191

2.  Why we should improve current practice of diagnosing and treating pulmonary large cell neuroendocrine carcinomas in patients with advanced disease.

Authors:  Jules Derks; Robert Jan van Suylen; Erik Thunnissen; Michael den Bakker; Harry Groen; Egbert Smit; Ronald Damhuis; Esther van den Broek; Ernst-Jan Speel; Anne-Marie C Dingemans
Journal:  Eur Respir J       Date:  2017-10-26       Impact factor: 16.671

Review 3.  Practical Guide to Surgical Data Sets: Surveillance, Epidemiology, and End Results (SEER) Database.

Authors:  Kemi M Doll; Alfred Rademaker; Julie A Sosa
Journal:  JAMA Surg       Date:  2018-06-01       Impact factor: 14.766

Review 4.  Inflammation and cancer: back to Virchow?

Authors:  F Balkwill; A Mantovani
Journal:  Lancet       Date:  2001-02-17       Impact factor: 79.321

5.  Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome.

Authors:  Lynnette Fernandez-Cuesta; Ernst-Jan M Speel; Anne-Marie C Dingemans; Jules L Derks; Noémie Leblay; Erik Thunnissen; Robert Jan van Suylen; Michael den Bakker; Harry J M Groen; Egbert F Smit; Ronald Damhuis; Esther C van den Broek; Amélie Charbrier; Matthieu Foll; James D McKay
Journal:  Clin Cancer Res       Date:  2017-10-24       Impact factor: 12.531

6.  Lung cell-specific expression of the murine surfactant protein A (SP-A) gene is mediated by interactions between the SP-A promoter and thyroid transcription factor-1.

Authors:  M D Bruno; R J Bohinski; K M Huelsman; J A Whitsett; T R Korfhagen
Journal:  J Biol Chem       Date:  1995-03-24       Impact factor: 5.157

7.  Adjuvant Chemotherapy Does Not Confer Superior Survival in Patients With Atypical Carcinoid Tumors.

Authors:  Kevin L Anderson; Michael S Mulvihill; Paul J Speicher; Babatunde A Yerokun; Brian C Gulack; Daniel P Nussbaum; David H Harpole; Thomas A D'Amico; Mark F Berry; Matthew G Hartwig
Journal:  Ann Thorac Surg       Date:  2017-07-29       Impact factor: 4.330

8.  Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.

Authors:  Arvind Dasari; Chan Shen; Daniel Halperin; Bo Zhao; Shouhao Zhou; Ying Xu; Tina Shih; James C Yao
Journal:  JAMA Oncol       Date:  2017-10-01       Impact factor: 31.777

9.  Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  A-M C Dingemans; M Früh; A Ardizzoni; B Besse; C Faivre-Finn; L E Hendriks; S Lantuejoul; S Peters; N Reguart; C M Rudin; D De Ruysscher; P E Van Schil; J Vansteenkiste; M Reck
Journal:  Ann Oncol       Date:  2021-04-20       Impact factor: 51.769

10.  Prognostic significance of combined preoperative platelet-to-lymphocyte ratio and lymphocyte-to-monocyte ratio in patients undergoing surgery with stage IB non-small-cell lung cancer.

Authors:  Yongqiang Chen; Weidong Wang; Xuewen Zhang; Xiangyang Yu; Kexing Xi; Yingsheng Wen; Gongming Wang; Xiaoli Feng; Lanjun Zhang
Journal:  Cancer Manag Res       Date:  2018-11-08       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.